Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
May 07, 2019 16:05 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA...
Kura Oncology to Report First Quarter 2019 Financial Results
April 30, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Participate in Two Upcoming Investor Conferences
March 06, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results
March 05, 2019 16:03 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway – – Data from three ongoing Phase 2 trials of tipifarnib anticipated this year – – Third drug candidate menin-MLL inhibitor...
Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
March 05, 2019 07:30 ET
|
Kura Oncology, Inc.
– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in...
Kura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
January 03, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at H.C. Wainwright Global Investment Conference
August 30, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
August 07, 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 06, 2018 16:05 ET
|
Kura Oncology, Inc.
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming...